Login to Your Account

Start-up Autolus brings 'something different' to busy CAR T space

By Nuala Moran
Staff Writer

Thursday, January 22, 2015
LONDON – Autolus Ltd. has launched with a £30 million (US$45.6 million) series A funding to develop chimeric antigen receptor (CAR) T-cell cancer therapies, which it claims will both overcome the serious side effects seen to date and move beyond B-cell targeting to address solid tumors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription